Similar CV Event Rates Seen for Generic, Brand Levothyroxine

Event rates did not differ for atrial fibrillation, myocardial infarction, congestive heart failure, stroke

woman gets physical exam

THURSDAY, June 27, 2019 (HealthDay News) -- Cardiovascular event rates are similar for patients with newly treated hypothyroidism receiving generic and brand levothyroxine (L-T4), according to a study published online April 26 in the Mayo Clinic Proceedings.

Robert C. Smallridge, M.D., from the Mayo Clinic in Jacksonville, Florida, and colleagues conducted a retrospective analysis to examine whether L-T4 preparation (generic versus brand) affected hospitalization for cardiovascular events. A total of 87,902 propensity score-matched patients initiating generic or brand L-T4 (43,951 patients per cohort) were included; patients were followed for a mean of one year.

The researchers found no differences in event rates between patients on generic and brand L-T4 therapy for four outcomes: atrial fibrillation (1.82 versus 2.19 per 1,000 person-years; hazard ratio [HR], 1.22 [95 percent confidence interval, 0.9 to 1.65]; P = 0.19), myocardial infarction (2.12 versus 1.83 per 1,000 person-years; HR, 0.86 [95 percent confidence interval, 0.64 to 1.17]; P = 0.35), congestive heart failure (2.27 versus 2 per 1,000 person-years; HR, 0.88 [95 percent confidence interval, 0.66 to 1.18]; P = 0.41), and stroke (3.1 versus 2.38 per 1,000 person-years; HR, 0.77 [95 percent confidence interval, 0.59 to 1]; P = 0.05). There were no differences after stratification by age group.

"If these observations are confirmed with longer-term follow-up, then either generic or brand L-T4 preparations may be used to treat hypothyroidism due to benign thyroid disorders, at least with respect to the risk of cardiovascular events," the authors write.

Abstract/Full Text

Physician's Briefing

Published on June 27, 2019

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ